Dynamic MapReport
World News   USA   California   Bay Area   Business   Bio Tech   Peninsula (46)
Peninsula, Bio Tech Timeline Tuesday, May 8 Bookmark and Share     Author
Search Bay Area News Atlas:
Solazyme's solid IPO  Startup that makes algae-based biofuel, raised nearly $200 million; the stock finished on the Nasdaq at $20.71 with a 15% gain Stock of InterMune soaring Pacific Biosciences shares jump over IPO  12.5 million shares opened higher than the offering price are pouring another $200 million - in addition to the $375 million it already received in VC FDA eyes fibromyalgia drug Geron approved to test stem cells Panel doesn't back Avastin for cancer Clean-tech IPO brings $78 M to Codexis  A startup that makes designer enzymes for pharmaceuticals and biofuel production, sold its shares for the first time on the Nasdaq exchange FDA clears drug for kidney cancer  Food and Drug Administration approved its cancer treatment Avastin for a new use, marking the sixth approval for the blockbuster drug Axe falls at Genentech  Anxiety rippled through Genentech as Roche began to cut rank-and-file jobs as it folds the South SF biotech firm into its global operations Drug Raptiva pulled from market  The unit of drugmaker Roch is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection Gilead To Buy CV Therapeutics For $1.4 B  Biotechnology company Gilead Sciences, known for its HIV drugs, said it will pay $20 per share in cash for Palo Alto-based CV Therapeutics Roche to take over Genentech for $47B
World News (13) World Bio Tech (28) USA (336) California (187) Bay Area (13) Bay Area Bio Tech (139) Business (1699) Bio Tech (139) Peninsula (46)
Geron (4) Aids Drug (2)
   Bay Area Freeways    Central San Mateo County (16)    Richest Towns    South San Mateo County (7)    Hayward Castro Valley San Leandro    Redwood City    San Mateo    SFO    101    Bay Area Bridges (3)    Foster City (14)    Menlo Park (6)

2017 (1) 2016 (1) 2015 (3) 2014 (6) 2013 (2) 2011 (4) 2010 (5) 2009 (9) 2008 (8) 2007 (1) 2006 (2) 2005 (1) 2004 (1) 2003 (2)
Peninsula on Wikipedia Peninsula on Web
Roche (16)   Bay Area Merger and Acquisition (252)   Bay Area Bio Tech (139)   Gilead (13)   Cancer (64)
Genentech to buy Seragon Pharmaceuticals Migraine drug developer acquired for up to $825 million Biotech deal could mean $350 million for Five Prime Therapeutics Gilead Sciences CEO joins billionaires' ranks Gilead profit beats estimates Genentech invests $285 million in biotech in state Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug  Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion to give Amgen access to a rapidly expanding cancer-drug market Solazyme CEO resigns Gilead to buy Pharmasset for $11 billion
Gilead beats Street 4Q forecasts Gilead Sciences beats estimates for 4th-quarter earnings Gilead Sciences beats Street 3Q forecasts Gilead profit beats Wall Street forecasts Horizon Pharma to buy Brisbane’s Hyperion Therapeutics  Horizon Pharma agreed to buy Brisbane’s Hyperion Therapeutics for $1.1 billion to gain drugs to treat rare metabolic diseases Roche buys Brisbane drugmaker InterMune for $8.3 billion


year 2017 Top ^

Feb.7   Foster City


year 2016 Top ^

Feb.2   Foster City


year 2015 Top ^

Oct.27   Foster City
Jul.28   Foster City
Mar.31   Brisbane


year 2014 Top ^

Aug.24   Brisbane
  Swiss pharmaceutical giant is expanding its respiratory disease treatments by acquiring InterMune at $74 per share in an all-cash transaction
Jul.2   Genentech
Jun.3   San Mateo
Mar.17   South SF
Mar.3   Foster City
Feb.5   Foster City


year 2013 Top ^

Oct.14   Genentech
Aug.27   South SF


year 2011 Top ^

Dec.28   South SF
Nov.21   Foster City
  Gilead Sciences Inc. has agreed to pay about $11 billion for drug developer Pharmasset Inc. in a huge bet on experimental hepatitis C treatments
May.27   South SF
Apr.27   Brisbane


year 2010 Top ^

Oct.28   Menlo Park
Aug.18   Palo Alto
Jul.30   Menlo Park
Jul.20   Genentech
Apr.22   Redwood City


year 2009 Top ^

Aug.2   Genentech
Jul.9   Genentech
Apr.8   Genentech
Mar.12   Foster City
  Genentech
  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
Mar.9   Genentech Roche-Genentech deal called close  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal Mar.6   Genentech Roche raises bid for Genentech  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent Feb.9   Genentech Roche launches $86.50-a-share bid  Swiss drugmaker officially launched its $42 billion hostile offer for the 44% of Genentech Inc. it doesn't already own Jan.30   Genentech Roche revives takeover bid of Genentech  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Nov.18   Genentech Avastin linked to higher risk of clots  A team of university researchers: Blockbuster cancer drug is linked to a significantly increased risk of blood clots in the veins Aug.27   South SF Cell Genesys Drug Trial Halts  Shares plunged more than 70% after a clinical trial of its cancer vaccine Gvax was stopped due to a higher number of deaths among patients Aug.13   Genentech Genentech rejects Roche's $43.7b bid Jul.21   Genentech Roche Offers $44B For Remaining Shares Jun.12   Foster City Invitrogen to buy Applied Biosystems
  Invitrogen agreed to pay $6.4 billion in cash and stock for scientific instruments maker Applera's Applied Biosystems Group Apr.30   Genentech Bad news on cancer drug Rituxan Apr.24   Genentech Court slashes $200 million from judgment Feb.22   Genentech FDA Clears Avastin for Breast Cancer  A Genentech drug received federal approval, a surprise decision

year 2007 Top ^

Dec.5   Genentech FDA Panel Rejects Avastin, stock drops


year 2006 Top ^

Jul.31   Genentech Tony Blair Visits Genentech Headquarters
Feb.13   Genentech Cancer Drug Trials Scaled Back

year 2005 Top ^

Jul.11   Genentech Profits Soar 73% in 2Q


year 2004 Top ^

Nov.4   Brisbane VaxGen gets contract for anthrax vaccine
  The government is purchasing 75 million doses of a new generation vaccine under an $877.5 million

year 2003 Top ^

May.19   Genentech Encouraging results with cancer drug
  Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45%
Feb.23   Brisbane AIDS vaccine developed by VaxGen
  An experimental vaccine does not protect most people, but showed promise in protecting blacks and Asians


Earnings Main Event: Roche buys Brisbane dru...
Peninsula, Bio Tech on Google Map

1. 2017-02-07 Gilead beats Street 4Q forecasts Foster City
2. 2016-02-02 Gilead Sciences beats estimates for 4th-quarter earnings Foster City
3. 2015-10-27 Gilead Sciences beats Street 3Q forecasts Foster City
4. 2015-07-28 Gilead profit beats Wall Street forecasts Foster City
F. 2015-03-31 Horizon Pharma to buy Brisbane’s Hyperion Therapeutics Brisbane
2014-08-24 Roche buys Brisbane drugmaker InterMune for $8.3 billion Brisbane
H. 2014-07-02 Genentech to buy Seragon Pharmaceuticals Genentech
I. 2014-06-03 Migraine drug developer acquired for up to $825 million San Mateo
J. 2014-03-17 Biotech deal could mean $350 million for Five Prime Therapeutics South SF


Add a favorite (file a bookmark) to Peninsula, Bio Tech Timeline

Please send feedback to: support@mapreport.com

Advertise on Peninsula, Bio Tech Page

To sell or purchase a home in the Peninsula complete this form
XML